While I was in Shanghai a few weeks ago, I learned more about the accelerated initiatives to help life science companies better understand the market in China.As governments around the world grapple with the challenge of reforming their ailing healthcare systems, China has moved faster and further than most.
And because we at STINSON Brand Innovation are exploring opportunities to accelerate the commercialization of medical treatments, we’re watching the ambitious plans in China to provide universal access, transform public hospitals, and create a superlative life sciences industry.
The resultant transformation -- if successful -- has the potential to catapult China into a leading position in healthcare innovation and advancement. Expertise ranges from traditional Chinese medicine to innovative stem cell and gene therapy research.
In light of this, we’d like to share information about the inaugural FT China Healthcare and Life Sciences Summit. The program will be held July 13, 2010 at the JW Marriott Hotel Shanghai at Tomorrow Square.
It will provide critical insights into this fast evolving market, its regulatory framework and financing requirements, and the steps companies should take to identify and meet China's changing healthcare needs, adjust their product portfolios, and expand their market focus.
The Financial Times, in partnership with the UK Programme of Events at Shanghai World Expo 2010, is bringing together senior public and private sector decision-makers from China and the UK to share their expertise in the operation of national healthcare systems and discuss the unprecedented opportunities being created across the entire value chain, from the provision of medical insurance, services, devices and IT, to the research and development of new drugs.
Themes to be covered include:
- Critical assessments of China's healthcare reform programme
- Experiences shared from the UK's state healthcare system, and lessons that can be learned from successful and unsuccessful reforms in other countries
- Capitalising on emerging opportunities in China's healthcare IT, medical devices, health insurance and medical services markets
- Seizing the opportunities in China's life sciences, assessing the implications of healthcare reform for pricing, distribution, marketing and product strategies
- Gaining a foothold in the evolving retail, wholesaling and OTC markets in China
- China as a new epicentre for life sciences innovation and investment, new frontiers in vaccines, stem cell and cutting-edge biomedical research
- Perspectives of financiers and investors on the growth potential and opportunities in China's expanding healthcare and life sciences markets
- George Baeder, Partner and Vice President, Monitor Group Asia
- Wilf Blackburn, CEO, Allianz China Life Insurance
- Canwen Jiang, Vice President and Head of R&D Asia, Genzyme Corporation
- James Li, Partner, Kleiner Perkins Caulfield & Byers
- Min Liang, Vice President and CSO, TTY Oncology (TOT), TTY Biopharm
- Li Ling, Professor of Economics, China Center for Economic Research, Peking University
- Roberta Lipson, CEO, Chindex International and Board Chair, United Family Hospitals and Clinics
- Rajesh Parekh, Director, Greater China Healthcare & Pharmaceutical Practice, McKinsey & Company
- Stefano Pessina, Executive Chairman , Alliance Boots
- Zhang Wei, Assistant Professor of Management, China Europe International Business School (CEIBS)
- Wang Xiaochuan, Chairman and CEO, Sundia MediTech
- Ben Zhou, Vice President and Managing Director, Dell Services Public Sector, Greater China
- Sarah Barber, Team Leader, Health Policy and Systems, World Health Organisation
- Wang Fucai, Chairman, Ruinian International
- Vicky Chen, Partner, China Healthcare Partnership, Martin Currie China
No comments:
Post a Comment